The drug was being developed as a potential treatment for various cancers. GSK said it is expanding from its current focus on blood and women's cancers into lung and gastrointestinal cancers, as well ...

Molecular Partners leverages DARPins for oncology treatments, but Novartis' exit raises concerns. Click here to read why ...

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take ...

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take ...

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

“SILC is dedicated to eliminating Long Covid worldwide, especially in under-resourced countries and communities, by bringing ...

A new jab which allows cancer patients to be treated with just one injection is set to be rolled out by the NHS for 15 different types of the disease. Patients will be able to receive the ...

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...